Oversight and Investigations

Chairman:  Tim Murphy (PA-18)
Responsibility for oversight of agencies, departments, and programs related to the jurisdiction of the full committee, and for conducting investigations.



Tim Murphy (PA), Chairman
David McKinley (WV), Vice Chairman
Michael C. Burgess, M.D. (TX)
Marsha Blackburn (TN)
Morgan Griffith (VA)
Larry Bucshon (IN)
Bill Flores (TX)
Susan Brooks (IN)
Markwayne Mullin (OK)
Richard Hudson (NC)
Chris Collins (NY)
Kevin Cramer (ND)
Joe Barton (TX)
Fred Upton (MI) (Ex Officio)


Diana DeGette (CO), Ranking Member
Jan Schakowsky (IL)
Kathy Castor (FL)
Paul Tonko (NY)
John Yarmuth (KY)
Yvette D. Clarke (NY)
Joseph P. Kennedy, III (MA)
Gene Green (TX)
Peter Welch (VT)
Frank Pallone, Jr. (NJ) (Ex Officio)

July 8, 2015 | Press Release

The Subcommittee on Oversight and Investigations, chaired by Rep. Tim Murphy (R-PA), has scheduled a hearing for Tuesday, July 14, at 2:00 p.m. in room 2322 of the Rayburn House Office Building. The hearing is entitled, “Medicare Part D: Measures Needed to Strengthen Program Integrity.”

July 8, 2015 | Press Release

WASHINGTON, DC – Leaders of the House Energy and Commerce and Ways and Means Committees this week demanded responses from Health and Human Services Secretary Sylvia Burwell and Treasury Secretary Jack Lew regarding payments the administration has made to insurance companies to subsidize cost-sharing under the health care law after the administration requested – but did not rece

July 8, 2015 | Letter

Excerpt: To date, HHS has not provided any documents of information in response to that request. The committees reiterate the February 3, 2015, request. Please provide the department’s responses to the committees by July 21, 2015.

July 7, 2015 | Press Release

WASHINGTON, DC – Bipartisan leaders of the House Energy and Commerce Committee today sent a letter to Food and Drug Administration Acting Commissioner Dr. Stephen Ostroff regarding the labeling of certain opioids, particularly the discrepancy between Extended Release and Long-Acting (ER/LA) opioid analgesics and Immediate Release (IR) opioid analgesics.

July 7, 2015 | Letter

Excerpt: In 2013, FDA adopted labeling changes affecting Extended Release and Long-Acting (ER/LA) opioid analgesics, requiring manufacturers to adopt the most restrictive language that can be found in drug labeling, a ‘black box’ warning about their potential for abuse, the risk of fatal overdose, and a warning that maternal use of these products during pregnancy can result in neonatal opioid w